Cell and gene therapy is an innovative approach for treating a variety of medical conditions by delivering genes, cells or genetic materials into patients' bodies. These therapies harness cells and genes to treat diseases by repairing or replacing faulty genetic material. Some of the key applications of cell and gene therapy include treatment of cancer, cardiovascular diseases, neurological disorders, hematologic problems and monogenic diseases. The growing prevalence of chronic and life-threatening diseases worldwide has accelerated the demand for more personalized and targeted treatment options, driving significant interest and investment in the development of cell and gene therapies.

The global cell and gene therapy market is estimated to be valued at US$ 21.08 billion in 2024 and is expected to exhibit a CAGR of 4.4% over the forecast period 2024 to 2031.


Key Takeaways

Key players operating in the Cell And Gene Therapy Market Size  include Tadano Ltd, Liebherr Group, Terex Corporation, Xuzhou Construction Machinery Group Co., Ltd, Sany Heavy Industry Co. Ltd, Zoomlion Heavy Industry Science and Technology Co., Kobelco Construction Machinery Co., Ltd, Manitowoc Cranes, Link-Belt Cranes, Kato Works Co. Ltd, Palfinger AG, Manitex International, Sichuan Changjiang Electric Co. Ltd, Altec Inc., Elliott Equipment Company, Böcker Maschinenwerke GmbH, Tadano Faun GmbH, Broderson Manufacturing Corp., Mühlhäuser GmbH & Co. KG, SENNEBOGEN Maschinenfabrik GmbH. Major players are focusing on expanding their manufacturing facilities and product portfolios to enter new markets and cater to the growing demand.

The increasing prevalence of cancer, cardiovascular diseases, genetic disorders and other chronic conditions worldwide has boosted the demand for more targeted cell and gene therapies. Ongoing clinical research is also establishing the efficacy of these therapies for a wider range of diseases.

Global pharmaceutical giants and biotech companies are investing heavily in cell and gene therapy research and product development. They are also pursuing partnerships and acquisitions to gain access to new technologies and bolster their R&D capabilities. This is supporting the expansion of the global cell and gene therapy market across key regions.

Market Drivers

The primary driver accelerating the cell and gene therapy market is the rising demand for personalized treatment options with higher efficiency. Cell and gene therapies offer more targeted approaches with potential for long-term efficacy compared to traditional drugs. Furthermore, advancements in gene editing technologies such as CRISPR are enabling development of novel cell and gene therapy products. Continued research validating the clinical benefits of these therapies coupled with their expanding applications in immune-oncology and regenerative medicine will fuel market growth over the coming years.

Current geopolitical tensions are impacting the growth of the cell and gene therapy market. The ongoing Russia-Ukraine conflict has disrupted supply chains and trade relations in Eastern Europe. Many global biopharma companies were sourcing raw materials like reagents, vectors, and cell culture media from Russia and Ukraine for clinical and commercial manufacturing. With trade barriers introduced due to sanctions, access to these critical inputs has become difficult. Alternative long-term supplies will need to be established to ensure continuous production.

The conflict has also shifted funding priorities for government and private donors. Investments earmarked for advancing immunotherapy R&D are being reallocated to humanitarian aid for Ukraine. This has temporarily slowed down clinical trials and new product development programs. To sustain long-term growth, market players must diversify their supplier networks beyond the involved regions and seek alternative funding avenues. Public-private partnerships can help recoup losses and accelerate the commercialization of new advanced therapies.

In terms of geographical presence, North America contributes the largest value share to the cell and gene therapy market currently. This is due to high disease prevalence, rapid FDA approvals, heavy investments in bio-industry, and strong reimbursement structure in the US and Canada. Europe is the second largest regional market helped by centralized regulatory approval pathways and increasing focus on personalized medicine in major countries.

Asia Pacific is poised to be the fastest growing regional market for cell and gene therapies during the forecast period. This is led by large patient pools, improving healthcare infrastructure, and government initiatives in countries like China, India, Japan and South Korea to boost the development of domestic biotech industries. Regulations are also being reformed to allow easier imports and adoption of advanced cell therapies. With pro-research policies, AsiaPacific offers lucrative future opportunities for market expansion.

Get more insights on This Topic- Cell And Gene Therapy Market